

RECEIVED
CENTRAL FAX CENTER**OCT 27 2005****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Jackson, et al.	
Application No.: 10/828,395	Group Art Unit: 1635
Filed: 4/19/2004	Examiner: Tracy Ann Vivlemore
Title: Method for Treatment of Angiogenic Disorders	Confirmation No: 5836
Attorney Docket No.: UBC.P-032	
Customer No.: 021121	

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450


RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

In response to the Office Action of October 17, 2005, Applicants hereby elect group I, that is antisense oligonucleotide therapeutics, and as a single nucleotide structure Seq. ID No. 5, which has the sequence CAGCAGCAGAGTCTTCATCAT.

This election is made without traverse.

Respectfully submitted,



Marina T. Larson Ph.D.
PTO Reg. No. 32,038
Attorney for Applicant
(970) 468-6600

I hereby certify that this paper and any attachments named herein are transmitted to the United States Patent and Trademark Office, Fax number: 571-273-8300 on October 27, 2005.



Marina T. Larson, PTO Reg. No. 32,038

October 27, 2005
Date of Signature